Status:
COMPLETED
Long-Term Olanzapine Treatment in Children With Autism
Lead Sponsor:
Drexel University
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Autism
Eligibility:
All Genders
3-12 years
Phase:
PHASE2
PHASE3
Brief Summary
This study will determine the short- and long-term safety and effectiveness of the drug olanzapine (Zyprexa®) for reducing symptoms of autism in children.
Detailed Description
Autism is a serious childhood disorder that can significantly impair functioning and development. Educational and psychosocial programs are standard treatments for autistic children, but drug therapy ...
Eligibility Criteria
Inclusion
- Diagnosis of autism
- Parent or guardian willing to provide informed consent
Exclusion
- Uncontrolled seizure disorder
- Medical illness other than autism affecting the whole body
- Obesity
- History of psychosis
- Impairment of voluntary movement
- History of olanzapine treatment
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00183404
Start Date
September 1 2004
End Date
October 1 2011
Last Update
August 15 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Drexel University College of Medicine at Friends Hospital
Philadelphia, Pennsylvania, United States, 19124